Arachelvi Dhandayuthapani, MD
Nephrology · Columbus, GANPI 1861422743
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,369 of the $1,695 with a category attached, or 80.7%. 16 manufacturers reported payments, led by AstraZeneca at 43.9% of the total. That places this record below the midpoint for nephrology clinicians in GA, where the typical reported total is $1,554.
Across 90 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$744
- Travere Therapeutics, Inc.$317
- Vifor Pharma, Inc.$120
- Akebia Therapeutics Inc$118
- Fresenius USA Marketing, Inc.$83
- Ardelyx, Inc.$71
- plus $242 from 10 others
Across 95 payments — averaging $1134.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$108K
What the payments were for
- Food & beverage$1,36981%
- Education$32719%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 29 | $744 |
| Travere Therapeutics, Inc. | 29 | $317 |
| Vifor Pharma, Inc. | 6 | $120 |
| Akebia Therapeutics Inc | 5 | $118 |
| Fresenius USA Marketing, Inc. | 4 | $83 |
| Ardelyx, Inc. | 4 | $71 |
| Cormedix Inc. | 1 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| GSK | 2 | $33 |
| OPKO Pharmaceuticals, LLC | 2 | $27 |
| Amgen | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Filspari$126
How this compares
$1,695 in reported general payments places this provider in the 50th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 286 | $191,349 |
| VelphoroSucroferric Oxyhydroxide | 56 | $177,249 |
| LokelmaSodium Zirconium Cyclosilicate | 108 | $70,655 |
| VeltassaPatiromer Calcium Sorbitex | 66 | $59,702 |
| Sevelamer Carbonate | 133 | $52,070 |
| JardianceEmpagliflozin | 24 | $15,154 |
| RayaldeeCalcifediol | 11 | $13,418 |
| DapagliflozinDapagliflozin Propanediol | 11 | $4,775 |
| Cinacalcet Hcl | 12 | $4,255 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 16 | $3,951 |
| Nifedipine ErNifedipine | 170 | $3,836 |
| Midodrine Hcl | 39 | $3,230 |
| Febuxostat | 17 | $2,429 |
| Eplerenone | 17 | $2,172 |
| SpsSodium Polystyrene Sulfon/Sorb | 11 | $2,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $744 | $262,004394 claims |
| Fresenius USA Marketing, Inc.Velphoro | $83 | $177,24956 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $27 | $13,41811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 388 nephrology providers in Georgia.
Other nephrology in Columbus
- Rajendran AlappanColumbus$87K
- Rajeev ChauhanColumbus$32K
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
- James TumlinLawrenceville$434K
- Salvatore ChillemiMarietta$287K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Don WilliamsonAugusta$104K
- Frederic Rahbari OskouiAtlanta$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.